Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Benzer Materyaller

• Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
  Yazar:: Jabbour, Elias, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
  Yazar:: Jabbour, Elias, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
  Yazar:: Jain, Preetesh, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
  Yazar:: Jabbour, Elias, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
  Yazar:: Quintás-Cardama, Alfonso, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)